Less than 10% of patients that would benefit from obesity jabs including Wegovy can access them, states the WHO as it issues its first recommendations on the therapies.
With more than one billion individuals worldwide currently classified as obese, it is advocating for increased and just availability to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"The new guidance acknowledges that excess weight is a lifelong illness that can be treated with holistic and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant hurdles to universal access to the treatments that can aid individuals in losing considerable body mass, explains the body.
Skinny Jab Shortage
Even under the present most optimistic case, the production of these medications could only cover approximately 100 million people – less than 10% of the global need, according to the health organization.
The recommendation encourages countries and companies to widen access, by strategies including voluntary licensing.
Exclusive production rights on semaglutide – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in several nations in 2026.
The Way Obesity Drugs Operate
The injections replicate a biological compound to delay gastric emptying, curb appetite and enhance feelings of fullness so users eat less.
Patients commonly see weight reduction within a few weeks of beginning the once-weekly jabs.
Research points to people may see weight return after a year of halting the drug, because their usual appetite come back.
Being carrying excess weight raises your likelihood for experiencing medical conditions, such as diabetes, heart disease, stroke, and specific cancers.
Excess weight impacts individuals in every country and was linked to over three and a half million fatalities worldwide in 2024, as per the WHO.
